Title :

Impact of diabetes mellitus in cancer patients treated by chemotherapy: a real-life study

Author(s) :

Mailliez, Aurélie [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167 [RID-AGE]
Ternynck, Camille [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Duhamel, Alain [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Ploquin, Anne [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Bertrand, Nicolas [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Vambergue, Anne [Auteur]
Hôpital Claude Huriez [Lille]
Turpin, Anthony [Auteur]
Hôpital Claude Huriez [Lille]
Université Sorbonne Paris Cité [USPC]
Hôpital Européen Georges Pompidou [APHP] [HEGP]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]

Conference title :

European Society of Medical Oncology 2020

City :

Paris

Country :

France

Start date of the conference :

2020-09-19

English keyword(s) :

cancer
chemotherapy
diabetes mellitus
drug tolerance

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Introduction: Diabetes Mellitus (DM) lead to multiples complications.We hypothesize that chemotherapy-related adverse events (AEs) could be increased in diabetic patients.Main objective: to compare the occurrence of severe ...
Show more >Introduction: Diabetes Mellitus (DM) lead to multiples complications.We hypothesize that chemotherapy-related adverse events (AEs) could be increased in diabetic patients.Main objective: to compare the occurrence of severe AEs corresponding to grade 3/4 AEs within 90 days following the onset of the chemotherapy between diabetic and non-diabetic patients. Methods: A retrospective monocentric study in Lille University Hospital Oncology Unit.Inclusion criteria: patients treated for a first cycle of chemotherapy between May 2013 and May 2016.Exclusion criteria: patients with an history of cancer whatever the treatment carried out.Results:609 patients were included, 490 (80.5%) non-diabetics and 119 (19.5%) diabetics (Figure 1). After multivariate adjustement on age at cancer diagnosis, sex, general status, type of cancer, type of chemotherapy, presence of metastases and denutrition, diabetics had an increased risk of G3/4 AEs within 90 days compared to non-diabetics patients (multivariate OR: 1,57 [1,02;2,42], p=0,04) (Table 3). More frequent AEs were infection (26%), haemotological toxicity (13%), endocrinological toxicity (13%) including hyperglycemia.Conclusion: Diabetes mellitus lead to an increased risk of G3/4 AE occuring early after the beginning of the chemotherapy. A better consideration of its impact by oncologists is warranted.Show less >

Language :

Anglais

Peer reviewed article :

Oui

Audience :

Internationale

Popular science :

Non

Collections :

• Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) - UMR 9020 - UMR 1277

Source :

Harvested from HAL